Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2005-04-26
2005-04-26
Kemmerer, Elizabeth (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S007100, C435S007200, C435S007210, C435S007230, C436S501000, C536S024100
Reexamination Certificate
active
06884577
ABSTRACT:
The present invention provides novel assay methods for identifying compounds that may have both estrogen agonist and antagonist properties. In particular, the assay use cells comprising promoters having an AP1 site linked to a reporter gene. Compounds capable of inducing or blocking expression of the reporter gene can thus be identified. The compounds may be further tested for the ability to modulate the standard estrogen response, as well.
REFERENCES:
patent: 5071773 (1991-12-01), Evans
patent: 5723291 (1998-03-01), Kushner et al.
patent: 6156723 (2000-12-01), Kushner et al.
patent: 0629697 (1994-12-01), None
patent: WO 9506754 (1995-09-01), None
Andersson et al., (1992) “Carcinogenic Effects of Adjuvan Tamoxifen Treatment ant Radiotherapy for Early Breast Cancer”Acta Oncologia31 (2), 259-263.
Angel and Karin, (1991) “The Role of Jun, Fos and the AP-1 complex in cell-production and transformation.”Biochimica et Biophysica Acta. 1072:129-157.
Anzai et al. (1989) “Stimulatory Effects of 4-Hydroxytamoxifen on Proliferation of Human Endometrial Adenocarcinoma Calls.”Cancer Res.49:2362-2365.
Berry, et al., (1990) “Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydryoxytamoxifen.”EMBO J.9(9), 2811-2818.
Bracke, et al., (1991) “Retinoic acid modulates both invasion and plasma membrane ruffling of MCF-7 human mammary carcinoma cells in vitro.”Br. J. Cancer63:867-872.
Dauvois, et al (1992) “Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover.”Proc. Natl. Acad. Sci. USA89:4037-4041.
Davis et al (1993) “Medical Hypothesis: Xenoestrogens as Preventable Causes of Breast Cancer.”Environmental Health Perspectives, 101 (5):372-377.
Doucas, et al. (1991) “Unregulated expression of c-Jun or c-Fos proteins but not Jun D inhibits oestrogen receptor activity in human breast cancer derived cells.”EMBO J.10(8):2237-2245.
Dubik, et al. (1992) “Mechanism of estrogen activation of c-myc oncegene expression.”Oncogene, 7:1587-1594.
Fawell et al. (1990) “Inhibition of estrogen receptor-DNA binding by the “pure” antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization.”Proc. Natl. Acad. Sci.vol. 87, pp. 6883-6887.
Gaub, et al., (1990) “Activation of the Ovalbumin Gene by the Estrogen Receptor Involves the Fos-Jun Complex.”Cell63:1267-1276.
Horovitz, (1992) “Cellular Heterogeneity and Mutant Oestrogen Receptors in Hormone Resistant Breast Cancer.”Cancer Surveys14:41-54 (1992).
Iino, et al, (1991) “Antiestrogen therapy for breast cancer: Current strategies and potential causes for therapeutic failure.”Cancer Treat. & Res.53:221-237.
Kato, et al (1992) “A Far Upstream Estrogen Response Element of the Ovalbumin Gene Contains everal Half-Palindromic 5′-TGACC-3′ Motifs Acting Synergistically.”Cell, vol. 68, pp. 731-742.
Kushner et al. (1990) “Construction of Cell Lines that Express High Levels of the Human Extrogen Receptor and Are Killed by Estrogens.”Molecular Endocrinology4(10):1465-1473.
Kushner, et al. (1992) Abstract,Cold Spring Harbor Symosium, Sep. 2-5.
Kushner, et al. (1995) “Tamoxifen and related antiestrogens are agonists of a novel pathway of estrogen receptor action.” Abstract No. D.Journal of Neurochemistry 64(Suppl. 1). Twenty-Sixth Meeting of the American Society for Neurochemistry, Santa Monica, CA. Mar. 5-9.
Kumar, et al. (1987) “Functional Domains of the Human Estrogen Receptor.”Cell, vol. 51, pp. 941-951.
Kumar and Chambon, (1988) “The estrogen receptor binds tightly to its responsive element as a ligan-induced homodimer.”Cell, vol. 55, pp. 145-156.
Leitman, et al. (1992) “The Core Promoter Region of the Tumor Necrosis Factor alpha-Gene Confers Phorbol Ester Responsiveness to Upstream Transcriptional Activators.”Molecular and Cellular Biology, 12:1352-1356.
Love, et al. (1991) “Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women.”Annals of Internal Med., 115:860-864.
Love, et al. (1992) “Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer.”New England J. Med., 326(13):852-856.
Merck Index (1989) “4281. Genistein.” 11thEdition, p. 686.
Merck Index (1989) “3653. Estradiol.” 11thp. 583.
Pons, et al. (1990) “A New Cellular Model of Response to Estrogens: A Bioluminescent Test to Characterize (Anti) Estrogen Molecules.”Biotechniques, 9:450-459.
Sambrook, et al. (1989)Molecular Cloning: A Laboratory Manual, Second Edition. Cold Spring Harbor Laboratory Press, NY. pp. 16.57-16.58.
Soto, et al. (1992) “An ‘In-Culture’ Bioassay to Asses the Extrogenicity of Xenobiotics (E-Screen).”Advances in Modern Environmental Toxicology. vol. 21.
Spatz, et al. (1992) “Responsiveness of the 5′-Flanking Region of the Brain Type Isozyme of Creatine Kinase to Estrogens and Antiestrogen.”J. Steroid Biochem. Molec. Biol.41(3-8): 711-714.
Sundstrom., et al (1990) “The Stimulation of Uterine Complement Component C3 Gene Expression by Antiestrogens.”Endocrinology126(3): 1449-1456.
Umayahara, et al (1994) “Estrogen Regulation of the Insulin-like Growth Factor I Gene Transcription Involves an AP-1 Enhancer.”Journal of Biological Chemistry, 269(23):16433-16442.
Wakeling (1990) “Therapeutic Potential of Pure Antiestrogens in the Treatment of Breast Cancer.”J. Steroid Biochem. Molec. Biol.37(6):771-775.
Wakeling (1993) “The future of new pure antiestrogens in clinical breast cancer.”Breast Cancer Research and Treatment. 25:1-9.
Webb, et al. (1992) “The Limits of the Cellular Capacity to Mediate an Estrogen Response.”Molecular Endocrinology. 6(2):157-167.
Webb, et al. (1995) “Tamoxifen activation of the estrogen receptor AP-1 pathway: Potential origin for the cell-specific Estrogen-like effects of antiestrogens.”Molecular Endocrinology9(4):443-456.
Williard, et al. (1995) “Screening and characterization of estrogenic activity from a hydroxystilbene library.”Chemistry&Biology, 2(1):45-51.
Wolff et al. (1993) “Blood Levels of Organochlorine Residues and Risk of Breast Cancer.”J. Natl. Cancer Inst.85:648-652.
Philips et al. (1993) “Estradiol increases and anti-estrogens antagonize the growth factor induced activator protein-1 activity in MCF7 breast cancer cells without afecting c-fos and c-jun synthesis”, J. Biol. Chem. 268 (19) 14103-14108.
Hunt C. Anthony
Kushner Peter
Lopez Gabriella
Webb Paul
Williard Renee
Hunter Tom
Kemmerer Elizabeth
Quine Intellectual Property Law Group P.C.
The Regents of the University of California
LandOfFree
Methods for screening compounds for estrogenic activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for screening compounds for estrogenic activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for screening compounds for estrogenic activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3374270